BEIJING, Oct. 10 (Xinhua) -- Lepu Medical Technology (Beijing) Co., Ltd. announced that it plans to invest 12.5 million U.S. dollars to join in series C funding of American biopharmaceutical company Rgenix.
According to a company filing, it would like to introduce first in-class drugs, including RGX-104 into China, conducting clinical trials and market development in the country.
The introduction of Rgenix's products not only complements the company's product line of cancer immunotherapy, but also forms a combination of tumor immunotherapy products with its own characteristics, enhancing the company's core competitiveness in tumor immunotherapy. (Edited by Ma Xin, maxin11@xinhua.org)
A single purchase
